Chad Kawa, MD
Gastroenterology · Provo, UTNPI 1962654681
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (43.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 73.7% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $12,802 and has fallen 96.7% since, to $428 in 2025. Among gastroenterology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $57.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$16K
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$511
- Johnson & Johnson$331
- Ovesco Endoscopy USA, Inc.$321
- Pfizer$283
- plus $1K from 26 others
What the payments were for
- Consulting fees$4,25019%
- Travel & lodging$9,72844%
- Food & beverage$8,15937%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 56 | $16,315 |
| AbbVie(2 entities) | 182 | $3,173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $511 |
| Johnson & Johnson | 23 | $331 |
| Ovesco Endoscopy USA, Inc. | 1 | $321 |
| Pfizer | 20 | $283 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $177 |
| Nestle Healthcare Nutrition Inc. | 7 | $172 |
| Gilead | 8 | $154 |
| Merck | 4 | $54 |
| Ironwood Pharmaceuticals, Inc | 4 | $54 |
| Braintree Laboratories, Inc. | 3 | $52 |
| Intercept Pharmaceuticals, Inc. | 4 | $51 |
| Organon | 4 | $47 |
| Shire North American Group Inc | 2 | $37 |
| UCB, Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Shionogi Inc | 2 | $33 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| QOL Medical, LLC | 2 | $32 |
| Amgen | 1 | $30 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $20 |
| Romark Laboratories, LC | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| Sanofi | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $11 |
| Ambu Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$6,064
- GENERAL - BILIARY DEVICES$950
- SPYGLASS$653
- EXALT Model D$636
- AXIOS$577
- GENERAL HEMOSTASIS$114
How this compares
$22,137 in reported general payments places this provider in the 90th percentile of 122 gastroenterology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 15 | $9,905 |
| Pantoprazole Sodium | 98 | $1,742 |
| Balsalazide Disodium | 12 | $1,666 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 90 | $1,628 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $599 |
| Sucralfate | 18 | $580 |
| Ursodiol | 21 | $562 |
| Metoclopramide Hcl | 28 | $534 |
| Nadolol | 24 | $484 |
| Dicyclomine Hcl | 19 | $407 |
| Omeprazole | 34 | $371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $3,173 | $9,90515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 122 gastroenterology providers in Utah.
Other gastroenterology in Provo
- Brett ThorpeProvo$12K
- Kurt BodilyProvo$9K
- Bryce HaslemProvo$6K
- Brandon DickinsonProvo$6K
- Thomas DickinsonProvo$4K
- Terry BoxSalt Lake City$302K
- Richard GilroySalt Lake City$192K
- Kyle EliasonOgden$128K
- Umaprasanna KarnamRiverton$120K
- Kathryn PetersonSalt Lake City$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.